Stocktoria
DANAHER CORP /DE/ DHR
DANAHER CORP /DE/ (DHR) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.63% (safety: safe). FY2025 revenue was $24.6B at a 14.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.55 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-22 | Wells Fargo | Equal-Weight (main) |
| 2026-07-22 | TD Cowen | Buy (main) |
| 2026-07-22 | Stifel | Buy (main) |
| 2026-07-22 | Guggenheim | Buy (main) |
| 2026-07-22 | RBC Capital | Outperform (main) |
| 2026-07-06 | Evercore ISI Group | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.071 |
| Retained earnings / assets | 0.562 |
| EBIT / assets | 0.056 |
| Equity / liabilities | 1.699 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DHR | DANAHER CORP /DE/ | 5/9 | 4.46 | 38.4 | +2.9% |
| ROP | ROPER TECHNOLOGIES INC | 5/9 | 3.14 | 22.2 | +12.3% |
| AME | AMETEK INC/ | 5/9 | 5.41 | 36.8 | +6.6% |
| KEYS | Keysight Technologies, Inc. | 5/9 | 5.15 | 66.1 | +8% |
| FTV | Fortive Corp | 6/9 | 2.85 | 32.4 | +1.9% |
| MKSI | MKS INC | 6/9 | 2.32 | 89 | +9.6% |
| ST | Sensata Technologies Holding plc | 5/9 | 3.27 | 217.7 | -5.8% |
About DANAHER CORP /DE/
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
FAQ
Is DHR financially healthy?
DANAHER CORP /DE/'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DHR pay a dividend, and is it safe?
Yes. DANAHER CORP /DE/ pays a dividend yielding about 0.63% with a 24.3% payout ratio, rated “safe” for safety.
How profitable is DHR?
In FY2025, DANAHER CORP /DE/ had a net margin of 14.7% and a return on equity of 6.9%.
Is DHR overvalued or undervalued?
DANAHER CORP /DE/ trades at about 40.8× trailing earnings — above its 10-year norm (10-year range 20.4×–43.3×, median 35.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DHR?
The average Wall-Street price target for DANAHER CORP /DE/ is $227.96, about 10.8% above the recent price, from 23 analysts (consensus: strong buy).
Is DHR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DANAHER CORP /DE/: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 38.4×, a dividend yield of 0.63%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.